Cover Image
市場調查報告書

自行注射器的全球市場:市場分析,企業簡介,市場規模,市場佔有率,市場成長,趨勢,預測

Global Self-Injections Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

出版商 Data Bridge Market Research Private Limited 商品編碼 587831
出版日期 內容資訊 英文 350 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
自行注射器的全球市場:市場分析,企業簡介,市場規模,市場佔有率,市場成長,趨勢,預測 Global Self-Injections Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
出版日期: 2017年09月01日 內容資訊: 英文 350 Pages
簡介

本報告提供自行注射器的全球市場調查,市場概要,各類型、用途、使用目的、給藥途徑、終端用戶、流通管道、地區的市場趨勢,市場規模的變化與預測,市場促進、阻礙因素及市場機會、課題分析,法規環境,市場佔有率,競爭情形,主要企業的簡介等系統性資訊。

第1章 簡介

第2章 市場區隔

第3章 市場概要

  • 促進因素
  • 阻礙因素
  • 市場機會
  • 課題

第4章 摘要整理

第5章 重要考察

第6章 法規環境

  • 概要
  • 美國:FDA
  • 歐洲:EC記號

第7章 償付制度

第8章 自行注射器的全球市場:各類型

  • 市場概要
  • 各產品類型
  • 無針注射器
  • 自動注射器
  • 筆型注射器
  • 穿戴式注射器

第9章 自行注射器的全球市場:各用途

  • 市場概要
  • 內分泌疾病
    • 糖尿病
    • 貧血
    • 生殖器系疾病
    • 骨質疏鬆症
    • 下垂體性矮小症
  • 腫瘤、癌症
  • 自體免疫疾病
    • 類風濕性關節炎
    • 多發性硬化症
    • 克隆氏症
    • 乾癬
    • 其他
  • 罕見疾病
  • 其他的用途
    • 疼痛管理
    • 過敏治療
    • 美容醫療
    • C型肝炎
    • 血友病

第10章 自行注射器的全球市場:各使用目的

  • 市場概要
  • 治療
  • 疫苗接種
  • 其他

第11章 自行注射器的全球市場:各給藥途徑

  • 市場概要
  • 皮膚
  • 血管、肌肉骨骼
  • 內臟器官
  • 中樞神經系統

第12章 自行注射器的全球市場:各終端用戶

  • 市場概要
  • 醫院、診療所
  • 居家照護
  • 研究機關
  • 製藥、生物科技企業
  • 其他

第13章 自行注射器的全球市場:各流通管道

  • 市場概要
  • 醫院內藥局
  • 零售藥局
  • 直接競標
  • 線上藥局

第14章 自行注射器的全球市場:各地區

  • 市場概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第15章 市場佔有率分析

  • 全球市場
  • 北美
  • 歐洲
  • 亞太地區

第16章 企業簡介

  • ELCAM MEDICALCOMPANY OVERVIEW
  • BESPAK
  • SANOFI
  • SANDOZ INTERNATIONAL GMBH
  • UNILIFE CORPORATION
  • WEST PHARMACEUTICAL SERVICES, INC
  • PFIZER INC.
  • IMPAX LABORATORIES, INC.
  • PENJET CORPORATION
  • CROSSJECT NEEDLE-FREE INJECTION SYSTEMS
  • WILHELM HASELMEIER GMBH & CO. KG
  • ANTARES PHARMA
  • BECTON, DICKINSON AND COMPANY
  • GERRESHEIMER AG
  • MYLAN N.V
  • NOVO NORDISK
  • OWEN MUMFORD LTD
  • PHARMAJET
  • SHL GROUP
  • YPSOMED

第17章 相關報告

目錄

Title:
Global Self-Injections Market
By Type (Devices (Needle-Free, Auto, Pen, Wearable Injectors), Formulations), Dosage Form, Therapeutic Application, Route of Administration, End-User, Distribution Channel,Geography(North America, Europe, APAC, MEA, South America) - Trends and Forecast to 2024.

The Global Self-Injections Market is accounted to reach USD 119.5 billion by 2024, from USD 23.4 billion in 2016, it is growing at the CAGR of 22.6 % in the forecast period 2017 to 2024..

The exponential growth is owing to multiple factors but the most prominent is development of biologic drugs for the treatment of autoimmune diseases, chronic diseases include heart disease, diabetes, stroke, and chronic respiratory problems.

The key market players for Global Self-Injections Market are listed below:

  • Abbvie, Inc.,
  • Antares Pharma,
  • 3M,
  • Becton Dickinson & Company
  • Baxter International Inc.,
  • Penjet Corporation,
  • PharmaJet,
  • GerresheimerAG,Pfizer Inc.,
  • Terumo Corporation,
  • Mylan N.V.,
  • SHL Group,
  • Bespak,
  • Janssen Biotech Inc.,
  • Insulet Corporation,
  • Unilife Corporation,
  • West Pharmaceutical Services, Inc.,
  • Ypsomed,
  • Eli lilly and Company,
  • Haselmeier AG,
  • Alkermes,
  • AptarPharma,
  • Credence MedSystems, Inc.,
  • SchottAG,
  • Ypsomed,
  • Owen Mumford Ltd.,
  • Glide Technologies,

The market is further segmented into:

  • Type
  • Application
  • End User
  • Geography

The formulations market is segmented into conventional drug delivery formulations, novel drug delivery formulations, and long-acting injection formulations. The conventional drug delivery segment is categorized into solutions, reconstituted/lyophilized formulations, suspensions and emulsions.

The novel drug delivery formulations market is segmented into colloidal dispersions, and microparticles. Colloidal dispersions market is further categorized into liposomes, niosomes, and polymeric/mixed micelles, and nano particles. Also, nanoparticles market is further segmented into nanosuspensions, nanoemulsions/microemulsions, and solid-lipid nanoparticles.

Based on therapeutic application, the market is segmented intoautoimmunediseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, and others. The market is also segmented based on dosage formintosingle dose and multi-dose.

Based on of route of administration, the market is segmented into skin, circulatory /musculoskeletal, organs, and central nervous system.

Based on end-user, the market is segmented into patient, physicians, home care settings and, others. The market is also segmented on the basis of distribution channel into hospital pharmacies, private clinics, chemist, and online pharmacies.

Based on geography, the Global Self-Injections market is segmented into geographical regions, such as,

  • North America,
  • Europe,
  • Asia-Pacific,
  • South America
  • Middle East & Africa

Covered in this report:

The report covers the present scenario and the growth prospects of the Global Self-Injections market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

1. INTRODUCTION

  • 1.1. OVERVIEW OF GLOBAL SELF-INJECTION MARKET
  • 1.2. CURRENCY AND PRICING
  • 1.3. LIMITATION
  • 1.4. MARKETS COVERED

2. MARKET SEGMENTATION

  • 2.1. MARKETS COVERED
  • 2.2. GEOGRAPHIC SCOPE
  • 2.3. YEARS CONSIDERED FOR THE STUDY
  • 2.4. CURRENCY AND PRICING
  • 2.5. RESEARCH METHODOLOGY
  • 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7. SECONDARY SOURCES
  • 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

  • 3.1. DRIVERS
    • 3.1.1. RISING CASES OF CHRONIC DISEASES
    • 3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
    • 3.1.3. GROWTH OF BIOLOGICS MARKET
    • 3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET
  • 3.2. RESTRAINTS
    • 3.2.1. HIGH COST OF DEVELOPMENT
    • 3.2.2. STRICT REGULATORY FRAMEWORK
  • 3.3. OPPORTUNITY
    • 3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS
      • 3.3.1.1. GENERICS
      • 3.3.1.2. BIOSIMILARS
    • 3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES
    • 3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS
  • 3.4. CHALLENGES
    • 3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
    • 3.4.2. PRODUCT RECALL
    • 3.4.3. STABILITY OF PRODUCTS
    • 3.4.4. STERILITY OF INJECTIONS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL SELF-INJECTION MARKET, REGULATORY

  • 6.1. OVERVIEW
  • 6.2. U.S. FDA APPROVAL
  • 6.3. CE MARKING (EUROPEAN CONFORMITY)

7. GLOBAL SELF-INJECTION MARKET, REIMBUSEMENT

  • 7.1. OVERVIEW
  • 7.2. REIMBURSEMENT SCENARIO

8. GLOBAL SELF-INJECTION MARKET, BY TYPE

  • 8.1. OVERVIEW
  • 8.2. GLOBAL SELF-INJECTION MARKET, BY PRODUCT TYPE
    • 8.2.1. NEEDLE FREE INJECTORS (NFI)
      • 8.2.1.1. NEEDLE FREE INJECTORS, BY PRODUCT

8.2.1.2. NEEDLE FREE INJECTORS, BY TECHNOLOGY LASER BASED NEEDLE FREE INJECTORS:VIBRATION BASED NEEDLE FREE INJECTORS:

      • 8.2.1.3. NEEDLE FREE INJECTORS, BY USABILITY REUSABLE NEEDLE-FREE INJECTORS DISPOSABLE NEEDLE-FREE INJECTORS
    • 8.2.2. AUTO INJECTORS
      • 8.2.2.1. AUTO INJECTORS, BY PRODUCT FILLABLE AUTO INJECTORS PRE-FILLED AUTO INJECTORS
      • 8.2.2.2. AUTO INJECTORS, BY TECHNOLOGY AUTOMATED AUTO INJECTORS MANUAL AUTO INJECTORS
      • 8.2.2.3. AUTO INJECTORS, BY DESIGN STANDARDIZED AUTO INJECTORS CUSTOMIZEDAUTO INJECTORS
      • 8.2.2.4. AUTO INJECTORS, BY USABILITY REUSABLE AUTO INJECTORS DISPOSABLE AUTO INJECTORS
    • 8.2.3. PEN INJECTORS
      • 8.2.3.1. PEN INJECTORS, BY PRODUCT SINGLE CHAMBERED PEN INJECTORS DUAL CHAMBERED PEN INJECTORS
      • 8.2.3.2. PEN INJECTORS, BY DESIGN STANDARD PEN INJECTORS CUSTOMIZED PEN INJECTORS
      • 8.2.3.3. PEN INJECTORS, BY USABILITY REUSABLE PEN INJECTORS DISPOSABLE PEN INJECTORS
    • 8.2.4. WEARABLE INJECTORS

9. GLOBAL SELF-INJECTION MARKET, BY APPLICATION

  • 9.1. OVERVIEW
  • 9.2. GLOBAL SELF-INJECTION MARKET, BY APPLICATION
  • 9.3. HORMONAL DISORDERS
    • 9.3.1. SELF-INJECTIONS FOR DIABETES
    • 9.3.2. SELF-INJECTIONSFOR ANEMIA
    • 9.3.3. REPRODUCTIVE HEALTH DISEASE
    • 9.3.4. OSTEOPOROSIS
    • 9.3.5. GROWTH HORMONE DISORDERS (GHD)
  • 9.4. ONCOLOGY
  • 9.5. AUTOIMMUNE DISEASES
    • 9.5.1. RHEUMATOID ARTHRITIS
    • 9.5.2. MULTIPLE SCLEROSIS
    • 9.5.3. CROHN'S DISEASES
    • 9.5.4. PSORIASIS
    • 9.5.5. OTHER AUTOIMMUNE DISEASES
  • 9.6. ORPHAN DISEASE
  • 9.7. OTHER APPLICATIONS
    • 9.7.1. PAIN MANAGEMENT
    • 9.7.2. ALLERGY TREATMENT
    • 9.7.3. AESTHETIC TREATMENTS
    • 9.7.4. HEPATITIS C
    • 9.7.5. HEMOPHILIA

10. GLOBAL SELF-INJECTION MARKET, BY USAGE PATTERN

  • 10.1. OVERVIEW
  • 10.2. CURATIVE CARE
  • 10.3. IMMUNIZATIONS
  • 10.4. OTHER USAGE PATTERN

11. GLOBAL SELF-INJECTION MARKET, BY MODE OF ADMINISTRATION

  • 11.1. OVERVIEW
  • 11.2. SKIN
  • 11.3. CIRCULATORY/ MUSKOSKELETAL
  • 11.4. ORGANS
  • 11.5. CENTRAL NERVOUS SYSTEM

12. GLOBAL SELF-INJECTION MARKET, BY END USER

  • 12.1. OVERVIEW
  • 12.2. HOSPITALS AND CLINICS
  • 12.3. HOME HEALTHCARE SETTINGS
  • 12.4. RESEARCH LABORATORIES
  • 12.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
  • 12.6. OTHER END USER

13. GLOBAL SELF-INJECTION MARKET, BY DISTRIBUTION CHANNEL

  • 13.1. OVERVIEW
    • 13.1.1. HOSPITAL PHARMACY
    • 13.1.2. PHARMACY STORES
    • 13.1.3. DIRECT TENDER
    • 13.1.4. ONLINE PHARMACY

14. GLOBAL SELF-INJECTION MARKET, BY GEOGRAPHY

  • 14.1. OVERVIEW
  • 14.2. NORTH AMERICA
    • 14.2.1. U.S.
    • 14.2.2. CANADA
    • 14.2.3. MEXICO
  • 14.3. EUROPE
    • 14.3.1. GERMANY
    • 14.3.2. FRANCE
    • 14.3.3. UK
    • 14.3.4. SWITZERLAND
    • 14.3.5. SPAIN
    • 14.3.6. ITALY
    • 14.3.7. NETHERLANDS
    • 14.3.8. RUSSIA
    • 14.3.9. TURKEY
    • 14.3.10. BELGIUM
    • 14.3.11. REST OF EUROPE
  • 14.4. APAC
    • 14.4.1. JAPAN
    • 14.4.2. CHINA
    • 14.4.3. SOUTH KOREA
    • 14.4.4. INDIA
    • 14.4.5. AUSTRALIA
    • 14.4.6. SINGAPORE
    • 14.4.7. THAILAND
    • 14.4.8. MALAYSIA
    • 14.4.9. INDONESIA
    • 14.4.10. PHILIPPINES
    • 14.4.11. REST OF APAC
  • 14.5. SOUTH AMERICA
    • 14.5.1. BRAZIL
    • 14.5.2. REST OF SOUTH AMERICA
  • 14.6. MEA
    • 14.6.1. SOUTH AFRICA
    • 14.6.2. REST OF MEA

15. GLOBAL SELF INJECTION MARKET, COMPANY LANDSCAPE

  • 15.1. COMPANY SHARE ANALYSIS: GLOBAL
  • 15.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 15.3. COMPANY SHARE ANALYSIS: EUROPE
  • 15.4. COMPANY SHARE ANALYSIS: APAC

16. COMPANY PROFILES

  • 16.1. ELCAM MEDICALCOMPANY OVERVIEW
    • 16.1.1. ELCAM MEDICAL: COMPANY SNAPSHOT
    • 16.1.2. PRODUCT PORTFOLIO
    • 16.1.3. RECENT DEVELOPMENTS
  • 16.2. BESPAK (SUBSIDIARY OF CONSORT MEDICAL COMPANY)
    • 16.2.1. COMPANY OVERVIEW
    • 16.2.2. BESPAK: REVENUE ANALYSIS
    • 16.2.3. PRODUCT PORTFOLIO
    • 16.2.4. RECENT DEVELOPMENTS
  • 16.3. SANOFI
    • 16.3.1. COMPANY OVERVIEW
    • 16.3.2. SANOFI : REVENUE ANALYSI
    • 16.3.3. PRODUCT PORTFOLIO
    • 16.3.4. RECENT DEVELOPMENTS
  • 16.4. SANDOZ INTERNATIONAL GMBH
    • 16.4.1. COMPANY OVERVIEW
  • 16.5. SANDOZ INTERNATIONAL GMBH: REVENUE ANALYSIS
    • 16.5.1. PRODUCT PORTFOLIO
    • 16.5.2. RECENT DEVELOPMENTS
  • 16.6. UNILIFE CORPORATION
    • 16.6.1. COMPANY OVERVIEW
    • 16.6.2. UNILIFE CORPORATION: REVENUEANALYSIS
    • 16.6.3. PRODUCT PORTFOLIO
    • 16.6.4. RECENT DEVELOPMENTS
  • 16.7. WEST PHARMACEUTICAL SERVICES, INC
    • 16.7.1. COMPANY OVERVIEW
    • 16.7.2. WEST PHARMACEUTICAL SERVICES, INC: REVENUE ANALYSIS
    • 16.7.3. PRODUCT PORTFOLIO
    • 16.7.4. RECENT DEVELOPMENTS
  • 16.8. PFIZER INC.
    • 16.8.1. COMPANY OVERVIEW
    • 16.8.2. PFIZER INC: REVENUE ANALYSIS
    • 16.8.3. PRODUCT PORTFOLIO
    • 16.8.4. RECENT DEVELOPMENTS
  • 16.9. IMPAX LABORATORIES, INC.
    • 16.9.1. COMPANY OVERVIEW
    • 16.9.2. IMPAX LABORATORIES, INC: REVENUE ANALYSIS
    • 16.9.3. PRODUCT PORTFOLIO
    • 16.9.4. RECENT DEVELOPMENTS
  • 16.10. PENJET CORPORATION
    • 16.10.1. COMPANY OVERVIEW
    • 16.10.2. PENJET CORPORATION: COMPANY SNAPSHOT
    • 16.10.3. PRODUCT PORTFOLIO
    • 16.10.4. RECENT DEVELOPMENTS
  • 16.11. CROSSJECT NEEDLE-FREE INJECTION SYSTEMS
    • 16.11.1. COMPANY OVERVIEW
    • 16.11.2. CROSSJECT NEEDLE-FREE INJECTION SYSTEMS: COMPANY SNAPSHOT
    • 16.11.3. PRODUCT PORTFOLIO
    • 16.11.4. RECENT DEVELOPMENTS
  • 16.12. WILHELM HASELMEIER GMBH & CO. KG
    • 16.12.1. COMPANY OVERVIEW
    • 16.12.2. HASELMEIER: COMPANY SNAPSHOT
    • 16.12.3. PRODUCT PORTFOLIO
    • 16.12.4. RECENT DEVELOPMENTS
  • 16.13. ANTARES PHARMA
    • 16.13.1. COMPANY OVERVIEW
    • 16.13.2. ANTARES PHARMA: REVENUE ANALYSIS
    • 16.13.3. PRODUCT PORTFOLIO
    • 16.13.4. RECENT DEVELOPMENTS
  • 16.14. BECTON, DICKINSON AND COMPANY
    • 16.14.1. COMPANY OVERVIEW
    • 16.14.2. BECTON, DICKINSON AND COMPANY: REVENUE ANALYSIS
    • 16.14.3. PRODUCT PORTFOLIO
    • 16.14.4. RECENT DEVELOPMENTS
  • 16.15. GERRESHEIMER AG
    • 16.15.1. COMPANY OVERVIEW
    • 16.15.2. GERRESHEIMER AG: REVENUE ANALYSIS
    • 16.15.3. PRODUCT PORTFOLIO
    • 16.15.4. RECENT DEVELOPMENTS
  • 16.16. MYLAN N.V
    • 16.16.1. COMPANY OVERVIEW
    • 16.16.2. MYLAN N.V.: REVENUE ANALYSIS
    • 16.16.3. PRODUCT PORTFOLIO
    • 16.16.4. RECENT DEVELOPMENTS
  • 16.17. NOVO NORDISK
    • 16.17.1. COMPANY OVERVIEW
    • 16.17.2. NOVO NORDISK: REVENUE ANALYSIS
    • 16.17.3. PRODUCT PORTFOLIO
    • 16.17.4. RECENT DEVELOPMENTS
  • 16.18. OWEN MUMFORD LTD
    • 16.18.1. COMPANY OVERVIEW
    • 16.18.2. OWEN MUMFORD LTD: COMPANY SNAPSHOT
    • 16.18.3. PRODUCT PORTFOLIO
    • 16.18.4. RECENT DEVELOPMENTS
  • 16.19. PHARMAJET
    • 16.19.1. COMPANY OVERVIEW
    • 16.19.2. PHARMAJET: COMPANY SNAPSHOT
    • 16.19.3. PRODUCT PORTFOLIO
    • 16.19.4. RECENT DEVELOPMENTS
  • 16.20. SHL GROUP
    • 16.20.1. COMPANY OVERVIEW
    • 16.20.2. SHL GROUP: COMPANY SNAPSHOT
    • 16.20.3. PRODUCT PORTFOLIO
    • 16.20.4. RECENT DEVELOPMENTS
  • 16.21. YPSOMED
    • 16.21.1. COMPANY OVERVIEW
    • 16.21.2. YPSOMED: REVENUE ANALYSIS
    • 16.21.3. PRODUCT PORTFOLIO
    • 16.21.4. RECENT DEVELOPMENTS

17. RELATED REPORTS

Back to Top